Targeted Immunotherapy Immunowake operates in oncology immunotherapy with a focus on patients unresponsive to existing treatments, signaling a potential sales opportunity for biotech partners, contract research organizations, and oncology-focused distributors seeking innovative therapeutic platforms.

Nimble Scale Small team size (2-10 employees) suggests a lean startup with likely high outsourcing needs for manufacturing, clinical trials, regulatory affairs, and specialized CRO partnerships to accelerate development and commercialization.

Recent Financing Recent funding rounds totaling around 23 million, plus board involvement from Hyfinity Investments, indicate growing investor interest and potential readiness for strategic alliances, licensing deals, or co-development arrangements.

Revenue Footing Current revenue range of 1 to 10 million with substantial funding positions Immunowake for early-stage partnerships, including feasibility studies, pilot programs, and channel partnerships with mid-sized biopharma distributors.

Digital & Platform Tech stack leveraging major platforms and web tools implies a modern online presence and potential to leverage digital partnerships, data collaboration, or tech-enabled collaboration models with research platforms and patient-focused initiatives.